What is Innogenix?
Innogenix, a generic pharmaceutical specialist, is dedicated to developing and manufacturing affordable and accessible healthcare solutions. The company serves a broad clientele, including pharmacies, hospitals, and healthcare providers, with a diverse product portfolio spanning multiple therapeutic categories. Innogenix's commitment to quality and regulatory compliance aims to improve patient outcomes through cost-effective medication alternatives.
How much funding has Innogenix raised?
Innogenix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Innogenix
PPP
Public-Private Partnership
What's next for Innogenix?
The substantial late-stage funding indicates Innogenix is poised for significant scaling and market penetration. This capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and expand distribution networks. The strategic nature of the recent investment suggests a focus on strengthening market position and potentially exploring new therapeutic areas or geographical expansions to solidify its role as a key provider of generic medications.
See full Innogenix company page
